Tovorafenib Approved for Some Children with Low-Grade Glioma - Cancer Currents Blog

National Cancer Institute sent this bulletin at 05/28/2024 11:01 AM EDT

Having trouble viewing this email? View it as a Web page.

Tovorafenib Approved for Some Children with Low-Grade Glioma
05/28/2024
	FDA has granted an accelerated approval to tovorafenib (Ojemda) for kids and teens who have low-grade glioma with changes in the BRAF gene. In a small clinical trial, the drug shrank or completely eliminated tumors in nearly 70% of patients.

You are subscribed to the latest posts from Cancer Currents: An NCI Cancer Research Blog from the National Cancer Institute. Update your subscriptions.